Larimar Therapeutics, Inc. (LRMR)
$
2.3
+0.31 (13.48%)
Key metrics
Financial statements
Free cash flow per share
-1.3672
Market cap
127.4 Million
Price to sales ratio
528.6951
Debt to equity
0.0337
Current ratio
7.4765
Income quality
0.9124
Average inventory
0
ROE
-0.5248
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company that is dedicated to developing innovative treatments for rare diseases through its proprietary cell penetrating peptide technology platform. The company incurred an income tax expense of $0.00 indicating its tax obligations, while the financial data pertains to the fiscal year 2024. Furthermore, the gross profit stands at $0.00 highlighting the company's profitability from core operations. In addition, the company earned an interest income of $0.00 showcasing its financial investments, alongside incurring an interest expense of $0.00 reflecting its debt servicing obligations as it advances its clinical programs. As Larimar progresses with its lead product candidate, CTI-1601, which is in Phase 1 clinical trials for the treatment of Friedreich's ataxia, these financial metrics underscore the company's capacity for sustained operations in the challenging biotechnology landscape while based in Bala Cynwyd, Pennsylvania. Currently, the stock is affordable at $2.30 suitable for budget-conscious investors looking to enter the market. Trading activity shows the stock has an average trading volume of 1,123,498.00 indicating moderate liquidity, which can be attractive for both short-term and long-term investors. With a market capitalization of $147,264,170.00 the company is classified as a small-cap player, representing a unique investment opportunity for those interested in high-growth potential ventures. As it continues to navigate the complexities of the biotechnology industry, it is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Larimar Therapeutics also belongs to the Healthcare sector, driving innovation and growth, which ensures its position as a frontrunner in advancing treatments for rare diseases while optimizing financial stability.
Is Larimar Therapeutics, Inc. (LRMR) a good investment?
Investing in Larimar Therapeutics, Inc. (LRMR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Larimar Therapeutics, Inc. (LRMR)'s stock forecast?
Analysts predict Larimar Therapeutics, Inc. stock to fluctuate between $1.61 (low) and $11.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Larimar Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Larimar Therapeutics, Inc.'s market cap is $147,264,170, based on 64,027,900 outstanding shares.
How does Larimar Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Larimar Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Larimar Therapeutics, Inc. (LRMR) stock?
To buy Larimar Therapeutics, Inc. (LRMR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LRMR. Place an order (Market, Limit, etc.).
What is the best time to invest in Larimar Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Larimar Therapeutics, Inc. stock ever split?
Larimar Therapeutics, Inc.'s last stock split was 1:12 on 2020-05-29.
How did Larimar Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.32 | Growth: 57.14%.
Where can I find Larimar Therapeutics, Inc.'s investor relations reports?
Visit https://www.larimartx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Larimar Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Larimar Therapeutics, Inc. stock?
All-time high: $20.55 (2021-02-04) | All-time low: $1.53 (2022-08-05).
What are the key trends affecting Larimar Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025 Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026 BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2025 operating and financial results.
globenewswire.com
2 months ago
BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
globenewswire.com
3 months ago
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
globenewswire.com
4 months ago
BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).
seekingalpha.com
5 months ago
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025.
benzinga.com
5 months ago
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
https://thefly.com
5 months ago
Citi analyst Samantha Semenkow notes Larimar Therapeutics announced initial data from the ongoing long-term Open Label Extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp and calls the market's negative reaction to the disclosure "at odds with what we view as a very positive dataset." The firm, which believes the market is "misinterpreting the two reported SAEs that led to discontinuations as a signal of a broader safety issue," believes the longer-term safety data reported today begin to confirm that nomlabofusp is safe and tolerable for chronic dosing. The firm, which views today's selloff as "overdone," would be "buyers on the dip" and maintains a Buy rating and $14 price target on Larimar shares.
benzinga.com
5 months ago
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
globenewswire.com
5 months ago
BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.
zacks.com
7 months ago
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
See all news
